NIH funding freeze halted a promising mRNA brain cancer trial for children — for 13 months
When DOGE-driven cuts ended the Pediatric Brain Tumor Consortium's federal funding, an experimental treatment for a disease that kills children within a year lost the infrastructure it needed to launch.
John Paul Macri was eight years old when he started tripping. His parents assumed clumsiness — until he began walking with his head tilted to one side and told his mother that when he held his head straight, everything looked double. Doctors found a mass in his brain. In March 2025, the diagnosis came back: DIPG, an inoperable brainstem tumor with a five-year survival rate of about 2%.
The prognosis we were told is that he would live anywhere between two and 11 months and there was nothing we could really do about it. You're just like 'What do you mean you can't help my son? We live in America and we have great healthcare.' It's just so hard to wrap your head around.— Katie Macri, John Paul's mother
John Paul's parents researched and found one treatment on the horizon: an experimental therapy using mRNA technology — the same platform behind the Covid vaccines — designed to train a child's immune system to attack the tumor. The scientists developing it were close to opening a clinical trial. Then the funding infrastructure that would have made that trial possible was dismantled.
In August 2025, the National Cancer Institute notified the Pediatric Brain Tumor Consortium — a network of academic centers and hospitals established by NCI in 1999 to support clinical trials for children with brain cancer — that it could no longer reapply for federal funding, according to Ira Dunkel, chair of the consortium. The move came amid a sweeping review of NIH grants by the Department of Government Efficiency. From February through August 2025, more than $2 billion was pulled or frozen from thousands of federally funded research projects.
The only rationale he had seen for the move was in a post on NCI's website, where a paragraph said the decision followed 'an assessment of how best to utilize its clinical trial resources for maximum impact.'— Ira Dunkel, chair of the Pediatric Brain Tumor Consortium
The practical consequences were immediate. Two clinical trials were shut down. Four others are being transferred to a larger hospital network. And for 13 months, no new patients could enroll in any of those studies, according to Dunkel. The mRNA trial being developed by Eugene Hwang with Elias Sayour suffered a delay of at least a year. The consortium would have provided the critical infrastructure needed to launch it.
It's incredibly frustrating. It's like taking this organism that took a long time to build and was functioning very well, and then killing it. Now we have to go build that organism again.— Eugene Hwang, brain cancer expert, Children's National Hospital
The Department of Health and Human Services offered a different framing. According to spokeswoman Emily Hilliard, the move to a larger network of hospitals and research sites is intended to speed the development of new treatments and was not driven by cost-cutting.
This decision was not a cost-cutting measure. Rather, it reflected the significant evolution of the pediatric cancer clinical trial landscape.— Emily Hilliard, spokeswoman, Department of Health and Human Services
Hilliard also said the Trump administration is 'firmly committed to advancing childhood cancer research,' and she indicated that NCI had taken steps to ensure continuity of care for all children enrolled in the consortium's trials, while maintaining that the transition had introduced no delays to potential treatments. Dunkel's account directly contradicts that last point.
I see this as a very unfortunate loss for the pediatric brain tumor community.— Ira Dunkel, chair of the Pediatric Brain Tumor Consortium
The disruption landed in an area of cancer research that was already severely underfunded. Federal cancer research funds directed toward childhood cancer amount to only about 4% of the total. Pediatric brain tumors, which rank among the leading causes of cancer death in children, receive an even smaller share of that already limited pool. According to CNBC, most funding for this work comes from foundations created by parents whose children died from brain tumors.
DIPG affects about 300 U.S. children each year, according to CNBC. It grows inside the brainstem, making surgical removal impossible, and it is notoriously resistant to drugs because of the difficulty of crossing the blood-brain barrier. Lisa Ward co-founded the Tough2gether Foundation after losing her son Jace to DIPG in 2021, three years after he was diagnosed at age 20. She likened the tumor to 'a spider web in a child's brain' and 'glitter in a bowl of jello,' and she argued that DIPG poses a fundamentally different kind of challenge from cancers where scientists are refining treatments that already exist.
You are trying to stop a runaway train.— Lisa Ward, co-founder, Tough2gether Foundation
The Children's Brain Tumor Project at Weill Cornell Medical Center called the consortium's defunding 'a tremendous step backward,' saying it 'will slow progress, fragment efforts, and ultimately cost lives,' according to CNBC.
The broader picture of childhood cancer in the United States is one of genuine progress shadowed by persistent gaps. Five-year survival across all childhood cancers rose from roughly six in ten young patients in 1975 to nearly nine in ten by 2017, according to a study published in the Journal of the National Cancer Institute and conducted by researchers at Ann & Robert H. Lurie Children's Hospital of Chicago. But that progress has been uneven. Survival rates for most cancer types were lower among Black children and teenagers than among their peers. Five-year survival for acute lymphoblastic leukemia — the most common childhood cancer — reached 95% by 2017, while survival for acute myeloid leukemia remains around 72% and for sarcomas around 74%. DIPG sits at the far end of that spectrum, with a five-year survival rate of about 2%.
For AML, sarcomas and high-risk neuroblastoma, children still need new and better treatments, and research on them should be a priority.— Lindsay Schwartz, MD, MS, pediatric oncologist, Ann & Robert H. Lurie Children's Hospital of Chicago
The future of federal research funding remains unsettled. Reports indicated that the Trump administration had prepared a draft executive order that would have given it authority to withhold NIH grants on the basis of political criteria, but that the White House retreated from those plans following objections from members of Congress. What remains is a 13-month gap in enrollment for trials targeting one of the deadliest childhood cancers — a gap measured not in policy abstractions but in the time children with DIPG do not have.
Families hold a lot of fundraising galas that they really don't feel like going to after losing a child.— Lisa Ward, co-founder, Tough2gether Foundation
Why it matters — For children diagnosed with DIPG — a cancer that typically kills within a year — a 13-month pause in clinical trial enrollment is not an administrative delay; it is time those children do not have.
⚠ Not yet confirmed
- The White House backed away from plans for an executive order that would have allowed it to block NIH grants not conforming to a certain political agenda, after members of Congress objected.
- HHS says the transition of trials to a larger hospital network will accelerate development of new treatments and has not delayed potential treatments.
Sources differ on Whether the defunding of the Pediatric Brain Tumor Consortium delayed treatments: Yes — two trials shut down, four transferred, 13-month enrollment gap, mRNA trial delayed at least one year. (cnbc.com (Ira Dunkel, Eugene Hwang)) vs No — NCI has worked to ensure continuity of care and the transition has not delayed potential treatments. (cnbc.com (Emily Hilliard, HHS))
Reported by cnbc.com, cancer.gov, cac2.org, luriechildrens.org
- John Paul Ipope of the Catholic Church in 1978